查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604583

解痙藥物市場：按藥物類型、給藥途徑、分銷管道和最終用戶分類 - 全球預測 2025-2030

Antispasmodics Drugs Market by Drug type (Dicyclomine Hydrochloride, Hyoscyamine, Loperamide Hydrochloride), Route of administration (Injectable, Oral, Sublingual), Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年解痙藥市值為135.7億美元，預計到2024年將達到147億美元，複合年成長率為8.36%，預計到2030年將達到238.3億美元。

解痙藥主要用於緩解肌肉痙攣，並透過減少胃腸道的過度肌肉收縮來發揮作用，有助於治療大腸激躁症(IBS) 和其他胃腸道疾病。由於生活方式的改變，胃腸道疾病的盛行率不斷上升，越來越多的老年人口對此類疾病的脆弱性更加明顯，以及對現有治療方法的認知不斷提高，這些都強調了這一需求。解痙藥的應用主要在醫療保健領域，作為主要最終用戶，醫院、診所和門診手術中心大量使用。主要成長要素包括大力研發投資，開發療效較好、副作用較少的新型解痙藥物，以及支持市場滲透的策略聯盟。此外，線上藥局連鎖店的激增正在使這些藥物的取得更加民主化，並為市場擴張創造了新的機會。然而，潛在的副作用、嚴格的監管要求以及學名藥滲透導致的利潤率潛在下降給市場成長帶來了挑戰。此外，低度開發地區的意識低落也是一個主要障礙。為了充分利用市場潛力，公司應專注於藥物配方和輸送機制的創新，包括在某些情況下永續的植物性選擇和精準靶向。此外，投資於全面的行銷策略和教育意識計劃可以幫助緩解挑戰並擴大消費群。市場因創新而蓬勃發展，為個人化醫療的研究和可改善患者治療效果的聯合治療的開發提供了利潤豐厚的機會。由於醫療創新和向以患者為中心的護理轉變所驅動的動態性質和不斷發展，保持市場策略的敏捷性和適應性對於永續成長仍然至關重要。

主要市場統計
基準年[2023] 135.7億美元
預測年份 [2024] 147億美元
預測年份 [2030] 238.3億美元
複合年成長率（%） 8.36%

市場動態：揭示快速發展的解痙藥市場的關鍵市場洞察

供需的動態交互作用正在改變解痙藥市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 大腸激躁症和腹部疾病的發生率很高
    • 提高患者意識層級並改善治療
    • 全球解痙藥物的核准增加
  • 市場限制因素
    • 解痙藥專利到期問題
  • 市場機會
    • 加大新型解痙藥研發投入
    • 投資並擴大學名藥生產設施
  • 市場挑戰
    • 老年人不恰當使用骨骼肌鬆弛劑

波特五力：開拓解痙藥市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解解痙藥市場的外部影響

外部宏觀環境因素在塑造解痙藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解解痙藥市場競爭狀況

對解痙藥市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣解痙藥物市場供應商績效評估

FPNV定位矩陣是評估解痙藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪了解痙藥物市場的成功之路

解痙藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 大腸激躁症和腹部疾病的發生率較高
      • 提高患者意識層級並改善治療
      • 世界各地抗驚厥藥物的核准增加
    • 抑制因素
      • 抗驚厥藥物專利到期問題
    • 機會
      • 加大抗驚厥新藥研發投入
      • 投資及擴大學名藥生產設施
    • 任務
      • 老年患者骨骼肌鬆弛劑的不當使用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 解痙市集藥物種類

  • 鹽酸雙環胺
  • 天仙子胺
  • 鹽酸洛哌丁胺

第7章解痙藥物市場：依給藥途徑

  • 可注射的
  • 口服
  • 舌下

第8章解痙藥市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章解痙藥物市場：依最終使用者分類

  • 醫院
  • 專業中心

第10章 北美及南美解痙藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區解痙藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲解痙市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Actiza Pharmaceutical Private Limited
  • Ambrosia Pharma
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • B JOSHI AGROCHEM PHARMA
  • Blue Cross Laboratories Pvt Ltd.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddys Laboratories Ltd.
  • Flamingo Pharmaceuticals Ltd
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Johnsons & Johnsons Services Inc.
  • Lexicare Pharma Pvt. Ltd.
  • McKesson Medical-Surgical Goverment Solutions LLC
  • Mylan NV
  • Nexus Pharmaceuticals Inc.
  • Noreva Biotech
  • Pfizer Inc.
  • Sanofi SA
  • Solitaire Pharmacia Private Limited
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Wellona Pharma Private Limited
Product Code: MRR-4103B31E08E9

The Antispasmodics Drugs Market was valued at USD 13.57 billion in 2023, expected to reach USD 14.70 billion in 2024, and is projected to grow at a CAGR of 8.36%, to USD 23.83 billion by 2030.

Antispasmodics drugs, primarily used to relieve muscle spasms, function by reducing excessive muscular contractions in the gastrointestinal tract and are instrumental in treating conditions like irritable bowel syndrome (IBS) and other gastrointestinal disorders. Their necessity is underscored by rising incidences of digestive disorders due to lifestyle changes, increasing geriatric population with a more pronounced vulnerability to such conditions, and a heightened awareness of available treatments. The application of antispasmodics primarily spans the healthcare sector, with hospitals, clinics, and ambulatory surgical centers being the primary end-users engaged in significant utilization. Key growth influencers include robust R&D investments directed towards developing novel antispasmodics with improved efficacy and fewer side effects, and the propensity for strategic collaborations boosting market penetration. Moreover, the surge in online pharmacy chains is democratizing access to these medications, creating fresh opportunities for expansion. However, market growth is challenged by potential side effects, stringent regulatory requirements, and the possibility of generic drug infiltrations reducing profit margins. Additionally, a lack of awareness in underdeveloped regions poses a significant hurdle. To harness the full potential of the market, businesses should focus on innovation in drug formulation and delivery mechanisms, possibly exploring sustainable plants-based options and advanced biotechnological methods for precision targeting. Furthermore, investing in comprehensive marketing strategies and educational awareness programs can mitigate challenges and expand consumer bases. The market thrives on innovation, presenting lucrative opportunities for research in personalized medicine and development of combination therapies that could enhance patient outcomes. With a dynamic nature and constant evolution driven by medical innovations and a shift towards patient-centric care, staying agile and adaptive in market strategies remains crucial for sustainable growth.

KEY MARKET STATISTICS
Base Year [2023] USD 13.57 billion
Estimated Year [2024] USD 14.70 billion
Forecast Year [2030] USD 23.83 billion
CAGR (%) 8.36%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antispasmodics Drugs Market

The Antispasmodics Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High incidences of irritable bowel syndrome and abdominal problems
    • Increasing patient awareness level and improvement in treatment
    • Rising antispasmodic medicines approvals worldwide
  • Market Restraints
    • Patent expiration issues of antispasmodic drugs
  • Market Opportunities
    • Growing investment in research and development of novel antispasmodic meds
    • Investment and expansion of generic drugs production facilities
  • Market Challenges
    • Inappropriate use of skeletal muscle relaxants in geriatric patients

Porter's Five Forces: A Strategic Tool for Navigating the Antispasmodics Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antispasmodics Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antispasmodics Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antispasmodics Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antispasmodics Drugs Market

A detailed market share analysis in the Antispasmodics Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antispasmodics Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antispasmodics Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antispasmodics Drugs Market

A strategic analysis of the Antispasmodics Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antispasmodics Drugs Market, highlighting leading vendors and their innovative profiles. These include Actiza Pharmaceutical Private Limited, Ambrosia Pharma, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, B JOSHI AGROCHEM PHARMA, Blue Cross Laboratories Pvt Ltd., Daiichi Sankyo Company, Limited, Dr. Reddys Laboratories Ltd., Flamingo Pharmaceuticals Ltd, Fresenius Kabi AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnsons & Johnsons Services Inc., Lexicare Pharma Pvt. Ltd., McKesson Medical-Surgical Goverment Solutions LLC, Mylan N.V., Nexus Pharmaceuticals Inc., Noreva Biotech, Pfizer Inc., Sanofi SA, Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Wellona Pharma Private Limited.

Market Segmentation & Coverage

This research report categorizes the Antispasmodics Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug type, market is studied across Dicyclomine Hydrochloride, Hyoscyamine, and Loperamide Hydrochloride.
  • Based on Route of administration, market is studied across Injectable, Oral, and Sublingual.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End-User, market is studied across Hospitals and Speciality Centres.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High incidences of irritable bowel syndrome and abdominal problems
      • 5.1.1.2. Increasing patient awareness level and improvement in treatment
      • 5.1.1.3. Rising antispasmodic medicines approvals worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiration issues of antispasmodic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing investment in research and development of novel antispasmodic meds
      • 5.1.3.2. Investment and expansion of generic drugs production facilities
    • 5.1.4. Challenges
      • 5.1.4.1. Inappropriate use of skeletal muscle relaxants in geriatric patients
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antispasmodics Drugs Market, by Drug type

  • 6.1. Introduction
  • 6.2. Dicyclomine Hydrochloride
  • 6.3. Hyoscyamine
  • 6.4. Loperamide Hydrochloride

7. Antispasmodics Drugs Market, by Route of administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral
  • 7.4. Sublingual

8. Antispasmodics Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Antispasmodics Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Speciality Centres

10. Americas Antispasmodics Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antispasmodics Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antispasmodics Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Actiza Pharmaceutical Private Limited
  • 2. Ambrosia Pharma
  • 3. Amneal Pharmaceuticals LLC
  • 4. Aurobindo Pharma Limited
  • 5. B JOSHI AGROCHEM PHARMA
  • 6. Blue Cross Laboratories Pvt Ltd.
  • 7. Daiichi Sankyo Company, Limited
  • 8. Dr. Reddys Laboratories Ltd.
  • 9. Flamingo Pharmaceuticals Ltd
  • 10. Fresenius Kabi AG
  • 11. GlaxoSmithKline PLC
  • 12. Hikma Pharmaceuticals PLC
  • 13. Johnsons & Johnsons Services Inc.
  • 14. Lexicare Pharma Pvt. Ltd.
  • 15. McKesson Medical-Surgical Goverment Solutions LLC
  • 16. Mylan N.V.
  • 17. Nexus Pharmaceuticals Inc.
  • 18. Noreva Biotech
  • 19. Pfizer Inc.
  • 20. Sanofi SA
  • 21. Solitaire Pharmacia Private Limited
  • 22. Strides Pharma Science Limited
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Wellona Pharma Private Limited

LIST OF FIGURES

  • FIGURE 1. ANTISPASMODICS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTISPASMODICS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTISPASMODICS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTISPASMODICS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTISPASMODICS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTISPASMODICS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. ANTISPASMODICS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. ANTISPASMODICS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023